AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00466505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/m2 iv week 1, then 250 mg/m2 weekly thereafter, starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
Study NCT00466505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: 200 mg po BID starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
Study NCT00466505 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: proteomic profiling
Description: Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction. We will use LC-MS-MS or MALDITOF mass spectrometry.
Study NCT00466505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: phospho-EGFR levels using western blots of tissue extracts and immunohistochemistry on frozen and (if no other option available, paraffinembedded tissue sections).
Study NCT00466505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction.
Study NCT00466505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: We will use LC-MS-MS or MALDITOF mass spectrometry. Before any tissues are received, the drug of interest is evaluated via MALDI mass spectrometry on a MDS/Sciex QStar QqTOF mass spectrometer.
Study NCT04240756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training
Description: Parents will receive 10 sessions of behavioral parent training with components specifically targeted toward parents with ADHD. Treatment will be delivered via telehealth.
Study NCT04240756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release mixed amphetamine salts (MAS)
Description: The MAS protocol will include a 2-4 -week open-label titration beginning at 20 mg and dose level will be increased weekly at telehealth visits with the psychopharmacologist until an optimal response or maximum dose of 60 mg.
Study NCT01285193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breath control
Description: A music CD with sound cues is used to guide the subject to breathe in a regular and slower rate. This is practiced for at least 15 minutes a day over 2 months.
Study NCT02336581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: individual + group + follow-up phone contacts
Study NCT02336581 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual (eTAU)
Description: individual + group + follow-up phone contacts
Study NCT03458429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMFFP
Description: Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma
Study NCT01750593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of the thyroid nodule
Description: Under USG control, the nodule will be ablated by radiofrequency with a needle that has an active tip of 1 cm.
Study NCT01346761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Genetic Counseling
Description: Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor over the telephone. Counseling sessions will be audiotaped for quality control of intervention.
Study NCT01346761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Genetic Counseling
Description: Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor in person. Counseling sessions will be audiotaped for quality control of intervention.
Study NCT03442023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate at 2%
Description: Mouth Rinse with Chlorhexidine gluconate at 2% every 12 hours, one week.
Study NCT03442023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate at 0.12%
Description: Mouth Rinse with Chlorhexidine gluconate at 0.12% every 12 hours, one week.
Study NCT01050075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture therapy
Description: acupuncture therapy
Study NCT01050075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary study
Study NCT01050075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: To be determined by the treating physician
Study NCT02774408 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Saturation sensitive backup ventilation
Study NCT01603420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luteinizing hormone-releasing hormone (LHRH)
Description: Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.
Study NCT01603420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone (LHRH)
Description: Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.
Study NCT01603420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 20mg/m2 IV every 7 days x 8 weeks.
Study NCT01603420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conformal Radiation Therapy (RT)
Description: 1.8 Gy(RBE) (or Gy for IMRT) per fraction,five fractions per week for a total dose of 79.2 Gy (RBE) (or Gy).
Study NCT01603420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conformal Radiation Therapy (RT)
Description: 1.8 Gy(RBE) (or Gy for IMRT) per fraction,five fractions per week for a total dose of 79.2 Gy (RBE) (or Gy).
Study NCT02822170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV amino acids and in-bed cycle ergometry
Description: IV amino acids and in-bed cycle ergometry
Study NCT03406793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard MNP
Description: Standard MNP, 15 micronutrients (Vitamin A 400 µg, vitamin D 5 µg, vitamin E 5 mg, vitamin C 30 mg, thiamine 0.5 mg, riboflavin 0.5 mg, niacin 6 mg, pyridoxine 0.5 mg, vitamin B12 0.9 mg, folate 150 µg, iron 10 mg, zinc 4.1 mg, copper 0.56 mg, selenium 17.0 µg and iodine 90 µg). Daily supplementation for 24 weeks.
Study NCT03406793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High zinc, low iron MNP
Description: Same as group 1, except with 10 mg zinc instead of 4.1 mg and 6 mg iron instead of 10 mg. Daily supplementation for 24 weeks.
Study NCT03406793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High zinc, low/no iron on alternating days
Description: Same as study group 1, except with 10 mg zinc instead of 4.1 mg, and 6 mg iron and no iron on alternating days instead of 10 mg. Daily supplementation for 24 weeks.
Study NCT03406793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dispersible zinc supplement
Description: 10 mg zinc in a dispersible tablet. Daily supplementation for 24 weeks.
Study NCT03406793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intermittent zinc supplement
Description: 10 mg zinc in a dispersible tablet. Daily supplementation for 14 days at baseline and 3 months, placebo tablet on all other days.
Study NCT03406793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: Daily provision of a placebo powder for 24 weeks.
Study NCT02100540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: I placebo capsule
Description: I placebo capsule
Study NCT02100540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: II RDC 0.3mg capsule
Description: II RDC 0.3mg capsule
Study NCT02100540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: III RDC 0.6mg capsule
Description: III RDC 0.6mg capsule
Study NCT03959774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPC NET
Description: a digital pack with connected bracelet and connected balance will be given to the patient. IPC NET and Nokia Health applications will be downloaded. Pairing between connected objects and the smartphone will be done during the inclusion visit
Study NCT03604263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArcticLine Cardiac Cryoablation Catheter
Description: Cryoablation
Study NCT02550132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: Participants will lie down during the 45-minute experimental session. Vertebral displacements (cm) and muscle response amplitude (RMS value) will be recorded through kinematic markers (on T6, T7 and T8 spinous processes) and surface electromyography electrodes (on the left and right erector spinae at T6 and T8 vertebra level). Each SMT (4 per participant) will be delivered at T7 transverse processes by an apparatus. Responses during the thrust phase (duration equal to twice the time to peak force) and after the thrust (1,5s duration) will be compared between SMTs.
Study NCT02550132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apparatus used to deliver spinal manipulations
Description: An apparatus using a servo-controlled linear actuator motor (Linear Motor Series P01-48x360, LinMot Inc., Switzerland) will be used to deliver spinal manipulations.
Study NCT00504257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Day 1, every 21 day cycle
Study NCT00504257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Day 1, 8, every 21 day cycle
Study NCT04007614 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Fardellone questionnaire (evaluation of calcium intake) Tolerance of treatment
Study NCT03585114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18] DCFPyL
Description: \[18F\]DCFPyL will be used for study imaging. It will be administered intravenously on the day of imaging. Subjects will receive a bolus injection of 9mCi (331 MBq) of \[18F\]DCFPyL through a peripheral IV catheter. 60 to 120 minutes after injection, a whole body (toes to vertex) lowdose CT will be obtained (120 kVp, 80 mA maximum).
Study NCT03585114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT imaging
Description: As per standard of care, acquisition will be performed on PET/CT scanner (Siemens, Germany) operating in 3D emission mode with CT-derived attenuation correction.
Study NCT00605826 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NASHA/Dx (Solesta) Gel
Description: Injection of 4 x 1ml of NASHA/Dx Gel at the start of the blinded phase.
Study NCT00605826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NASHA/Dx (Solesta) Gel
Description: Injection of 4 x 1ml of NASHA/Dx Gel at the start of the blinded phase.
Study NCT00605826 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sham Injection
Description: Sham injection at the start of the blinded phase.
Study NCT00605826 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: Sham injection at the start of the blinded phase.
Study NCT01706913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dermatology consult
Study NCT02000843 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: tympanoplasty -- conchal cavum approach
Description: Incision is made inside the ear canal. It is extended into the conchal cavum. The incision allows a direct approach to the eardrum, and also allow easy harvesting of the perichondrium to be used as graft material.
Study NCT03214835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endo CDx Brush biopsy
Description: In patients with laryngeal lesion the brush biopsy will be taken with the standard cup biopsy - either in the clinic or in the OR. In LPR patients brush biopsy will be taken in the clinic.
Study NCT00562419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-322
Description: IV solution, weekly
Study NCT00562419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: IV solution, biweekly
Study NCT01175512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
Study NCT01175512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
Study NCT01172080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protocol of reminders regarding due colonoscopy
Description: Participants receive two standardized letters followed by a phone call if they have not scheduled or completed their upcoming due colonoscopy
Study NCT03386708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intrauterine injection
Description: intrauterine injection with umbilical cord mesenchymal stem cell (SCLnow 19#); one time/one menstrual cycle, total 2 times
Study NCT03386708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cell
Description: 2 \* 10\^7 cells (2ml)
Study NCT02365428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity text messages
Study NCT01104220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: Bariatric surgery-induced weight loss to achieve \~20%-30% reduction in initial body weight
Study NCT01530490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline and Hydroxyethyl Starch
Description: 0.5mg
Study NCT01530490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl Starch
Description: 0.5 mg cabergoline administration 8 days
Study NCT00296322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin, mitomycin-C, doxifluridine
Description: Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)~iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)
Study NCT02793284 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL PET/CT scan
Description: PET/CT scan using the radioactive agent 18F-DCFPyL
Study NCT00684814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Tartrate 10 mg tablet
Description: 10 mg tablet administered after an overnight fast of at least 10 hours
Study NCT00684814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem Tartrate 10 mg tablet (Ambien®)
Description: 10 mg tablet administered after an overnight fast of at least 10 hours
Study NCT00643149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: 10 day regimen, 45 mg/kg/day, given in divided doses every 12 hours
Study NCT00643149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin SR
Description: 60 mg/kg dose of azithromycin SR was as safe and effective as a 10-day regimen of amoxicillin when used to treat children with strep throat
Study NCT04519554 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Endometrial sampling
Description: Endometrial sampling with 2 different forceps
Study NCT03596164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
Study NCT03596164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe
Description: Teduglutide will be administered using syringe. Syringe is approved for use in Japan by PMDA.
Study NCT03596164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.
Study NCT03596164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vial Adapter for Device
Description: Vial adapter for device is approved for use in Japan by PMDA.
Study NCT02635230 — intervention group
Intervention type: DRUG
Intervention: Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.
Study NCT04227691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-pulsed Nd Yag laser treatment
Description: One treatment of the assigned axilla with long-pulsed Nd YAG laser treatment in ten patients
Study NCT04227691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IPL treatment
Description: One treatment of the assigned axilla with IPL treatment in ten patients
Study NCT01676961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: romiplostim
Description: Given SC
Study NCT03929419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal insulin
Description: application of 160 units human insulin
Study NCT03929419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spray
Description: nasal spray containing placebo solution
Study NCT01398436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: central venous catheter positioning in right atrium
Description: A central venous catheter will be advanced for its entire length unless arrhythmias develop. Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography
Study NCT01951066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Implant
Description: Patients will receive a single injection of a dexmethasone implant
Study NCT01951066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF injection
Description: Patients will receive PRN injections of an anti-VEGF agent
Study NCT00679198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse-patient communication
Description: We will train home health nurses to act as patient advocates by communicating the risks and benefits of osteoporosis treatment to patients and their healthcare providers.~Thus, we will provide a comprehensive, integrated approach to the management of osteoporosis among patients with a history of insufficiency fractures that is highly generalizable to a national setting.
Study NCT04608864 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: varicocelectomy
Description: microsurgical subinguinal varicocelectomy
Study NCT01198158 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01198158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03377088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rose oil
Description: Rose oil will be given as the intervention in this study, an over-the-counter agent that can be commonly found in retail stores. It will be delivered as 2 drops 50% rose oil in water on a cotton ball within 20 cm of the patient's face for 30 minutes.
Study NCT04012255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (administered by DV3396 pen)
Description: Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 21 weeks
Study NCT04012255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide (administered by PDS290 pen)
Description: Increasing doses of semaglutide given sc in the stomach for 21 weeks
Study NCT00597649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicifadine
Description: SR dosage form of 400 mg bid or tid for one year
Study NCT03377088 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Almond Oil
Description: Almond Oil has been shown in limited studies to act as a placebo for pain control when compared to Rose Oil. This subtly sweet oil will be used to ensure the patient always receives a smell, and maintains blinding.
Study NCT02316613 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Study NCT02782468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat 25 mg/m^2
Description: Pevonedistat 25 mg/m\^2 intravenous infusion.
Study NCT02782468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat 44 mg/m^2
Description: Pevonedistat 44 mg/m\^2 intravenous infusion.
Study NCT02782468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat 10 mg/m^2
Description: Pevonedistat 10 mg/m\^2 intravenous infusion.
Study NCT02782468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat 20 mg/m^2
Description: Pevonedistat 20 mg/m\^2 intravenous infusion.
Study NCT02782468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m^2
Description: Azacitidine 75 mg/m\^2 intravenous or subcutaneous formulation.